IP Verse

Brand Murray Fuller competitive analysis

Explore the latest publications and patents granted to Brand Murray Fuller, showcasing their recent innovations and technological advancements.

Explore patent oppositions filed by Brand Murray Fuller against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3914247	Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry Disease	AMICUS THERAPEUTICS	Aug 13, 2025
EP3226841	Anticancer Compositions	ARAGON PHARMACEUTICALS	Jul 9, 2025
EP4062916	Methods Of Treating Fabry Patients Having Renal Impairment	AMICUS THERAPEUTICS	Jul 9, 2025
EP4241849	Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab	F HOFFMANN LA ROCHE	Jun 18, 2025
EP3487881	Methods Of Treating New-Onset Plaque Type Psoriasis Using Il-17 Antagonists	NOVARTIS	May 21, 2025
EP3781210	Treatment Of Sepsis And Septic Shock	COMBIOXIN	May 6, 2025
EP3840753	Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla Gene	AMICUS THERAPEUTICS	Apr 24, 2025
EP3889181	Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jan 24, 2025
EP2662094	Cylodextrin Complexation Methods For Formulating Peptide Proteasome Inhibitors	ONYX THERAPEUTICS	Jan 17, 2025
EP3150200	Pharmaceutical Composition, Pharmaceutical Dosage Form, Process For Their Preparation, Methods For Treating And Uses Thereof	BOEHRINGER INGELHEIM	Jan 10, 2025

Discover the latest PTAB cases involving Brand Murray Fuller, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Brand Murray Fuller with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced	Strategy Type
BRAND MURRAY FULLER	20	-	-	-	Highly Aggressive
AMICUS THERAPEUTICS	-	12	-	-	Non-Active
BOEHRINGER INGELHEIM	3	129	2	1	Defensive
NOVARTIS	6	406	-	21	Defensive